Clostridium difficile in Horses: Antimicrobial-Associated Diarrhea and Colitis in Foals and Adults

Etiology and Taxonomy

Clostridium difficile, reclassified as Clostridioides difficile, is an anaerobic, spore-forming, Gram-positive bacillus that causes enterocolitis in a range of mammalian hosts, including horses. The organism produces two primary exotoxins: toxin A (TcdA), an enterotoxin, and toxin B (TcdB), a cytotoxin. Both toxins are large clostridial glucosyltransferases that inactivate Rho-family GTPases within host intestinal epithelial cells, leading to actin cytoskeleton disruption, tight junction compromise, and apoptotic cell death [1]. Some strains also produce a third toxin, binary toxin (CDT), which is an ADP-ribosyltransferase that modifies actin and may enhance colonization and virulence.

The polysaccharide surface antigens PSI and PS-II are conserved cell wall components that have been investigated as vaccine targets. The pentasaccharide repeating block of PSI has been synthesized and conjugated to exotoxin B subunit for immunogenicity studies in horses [2]. Serum IgG antibodies against PSI have been detected in naturally exposed horses, indicating that this antigen is immunogenic during infection [2].

Epidemiology

Clostridium difficile is a significant cause of antimicrobial-associated diarrhea and colitis in both foals and adult horses. The organism is found in the intestinal tract of healthy horses at variable prevalence rates. Studies from northern Italy reported isolation rates of 5.7% in healthy horses, with ribotype diversity including types 012, 014, and 020 [3]. In Sweden, prevalence in hospitalized horses ranged from 9.5% to 21.7%, with environmental contamination of stalls being a major source of nosocomial transmission [4, 5].

Ribotypes circulating in equine populations overlap with those found in humans and other animals. In Brazil, ribotypes 014/020, 106, and 126 were identified in horses, demonstrating potential for interspecies transmission [6]. The zoonotic and anthroponotic implications of these shared ribotypes underscore the importance of infection control in veterinary settings.

Risk factors for C. difficile infection (CDI) in horses include hospitalization, antimicrobial therapy, dietary changes, and stress. Foals are particularly susceptible due to their immature intestinal microbiota and immune system. The disease is most commonly observed in neonates and young foals, but adults can also develop severe colitis [5, 7].

Antimicrobial-Associated Diarrhea and Colitis

The association between antimicrobial administration and C. difficile colitis in horses is well documented. A multicenter prospective study across three equine referral practices found that antimicrobial use was a significant risk factor for diarrhea, with odds ratios varying by drug class [8]. Macrolide antibiotics, particularly erythromycin, have been strongly implicated. In Sweden, erythromycin ethylsuccinate administration was associated with acute colitis in adult horses, with C. difficile isolated from a high proportion of cases [9].

A notable epidemiological scenario involves mares whose foals are treated with erythromycin and rifampicin for Rhodococcus equi pneumonia. These mares develop acute colitis, likely due to ingestion of antimicrobial residues from the foal's feces or direct environmental contamination [10]. This phenomenon highlights the potent effect of macrolides on the equine intestinal microbiota and the subsequent risk of C. difficile overgrowth.

Other antimicrobial classes associated with CDI in horses include beta-lactams, potentiated sulfonamides, and clindamycin. The disruption of the normal colonic microbiota reduces colonization resistance, allowing C. difficile spores to germinate and vegetative cells to proliferate [5].

Pathogenesis

The pathogenesis of C. difficile colitis involves a multistep process. Spores are ingested from a contaminated environment. After germination in the small intestine, vegetative cells colonize the large intestine. Toxin production occurs during logarithmic growth. Toxin A and toxin B bind to intestinal epithelial cell receptors, are internalized, and catalyze the glucosylation of small GTPases (Rho, Rac, Cdc42). This disrupts the actin cytoskeleton, leading to cell rounding, tight junction opening, and increased intestinal permeability [1].

The resulting fluid and electrolyte loss produces diarrhea. In severe cases, pseudomembrane formation, mucosal hemorrhage, and transmural inflammation occur. The host inflammatory response, mediated by neutrophil infiltration and cytokine release, contributes to tissue damage. Epithelial ion transporters, including the Na+/H+ exchanger (NHE3) and the cystic fibrosis transmembrane conductance regulator (CFTR), are dysregulated during infection, exacerbating secretory diarrhea [1].

In foals, experimental infection with toxigenic C. difficile strains reproduces the clinical disease, confirming the causal role of these toxins [11]. Co-infection with Clostridium perfringens type C has been documented in foals, suggesting that polymicrobial interactions may influence disease severity [12]. Clostridium perfringens type A has also been isolated from foals with acute enterocolitis, though its role as a primary pathogen in this context remains less clear [13, 14].

Clinical Signs

Clinical signs of C. difficile infection in horses range from mild, self-limiting diarrhea to severe, fatal colitis. In foals, the disease typically presents as acute onset of profuse, watery diarrhea, often with a foul odor. Affected foals may exhibit depression, anorexia, fever, and signs of abdominal pain (colic). Dehydration, electrolyte imbalances, and metabolic acidosis develop rapidly. In severe cases, toxemia, endotoxemia, and shock ensue [11, 5].

In adult horses, the clinical presentation includes acute diarrhea, colic, and fever. Feces may be watery, hemorrhagic, or contain pseudomembranous casts. Anorexia, depression, and tachycardia are common. Some horses develop peracute disease with rapid progression to shock and death within 24 to 48 hours. Chronic or recurrent cases are less common but have been reported.

Pathology

Gross pathological findings in horses with C. difficile colitis include congestion, edema, and hemorrhage of the colonic and cecal mucosa. The intestinal wall may be thickened, and the lumen may contain watery, blood-tinged fluid. Pseudomembranes, composed of fibrin, mucus, and cellular debris, may be adherent to the mucosal surface. In severe cases, mucosal ulceration and necrosis are present.

Histopathological examination reveals acute, necrotizing, pseudomembranous colitis. The lamina propria is infiltrated by neutrophils, and the crypt epithelium shows degeneration, necrosis, and sloughing. Microthrombi may be observed in submucosal vessels. In foals, lesions are often most severe in the cecum and large colon [11, 5].

Laboratory Diagnosis

Accurate laboratory diagnosis of C. difficile infection in horses requires a combination of tests to detect the organism, its toxins, or toxin genes. A diagnostic algorithm is presented in Figure 1.

flowchart TD
    A[Fecal sample from horse with diarrhea], > B{Initial screening}
    B, > C[Glutamate dehydrogenase (GDH) immunoassay]
    C, >|Positive| D{Toxin A/B detection}
    C, >|Negative| E[CDI unlikely; consider other pathogens]
    D, > F[ELISA or immunochromatographic test for toxins A/B]
    F, >|Positive| G[Confirmed CDI]
    F, >|Negative| H{Discrepant result}
    H, > I[PCR for toxin genes tcdA, tcdB, cdtA/B]
    I, >|Positive| J[Probable CDI; toxigenic strain]
    I, >|Negative| K[Non-toxigenic strain; CDI unlikely]
    G, > L[Optional: Anaerobic culture + ribotyping]
    J, > L
    K, > M[Consider other enteric pathogens]

Figure 1. Diagnostic algorithm for Clostridium difficile infection in horses.

Glutamate Dehydrogenase Detection

Glutamate dehydrogenase (GDH) is a constitutively produced enzyme present in both toxigenic and non-toxigenic C. difficile strains. Immunoassays for GDH serve as sensitive screening tests. A negative GDH result has a high negative predictive value and can rule out CDI. However, GDH detection does not differentiate between toxigenic and non-toxigenic strains, so positive results require confirmation with toxin detection [15, 16].

Toxin Detection

Detection of toxins A and B in feces is the cornerstone of CDI diagnosis. Enzyme-linked immunosorbent assays (ELISA) and immunochromatographic tests are commercially available and widely used in veterinary diagnostic laboratories. These assays use monoclonal or polyclonal antibodies against TcdA and TcdB. In foals and neonatal piglets, immunochromatographic tests have shown good agreement with ELISA for GDH and toxin detection, making them suitable for point-of-care use [16].

Tissue culture cytotoxicity assays, which detect the cytopathic effect of toxin B on cell monolayers, are considered a reference method but are less practical for routine diagnostics due to the need for cell culture facilities and the 24 to 48 hour turnaround time.

Molecular Detection

Polymerase chain reaction (PCR) assays targeting the toxin genes tcdA, tcdB, and the binary toxin genes cdtA and cdtB are highly sensitive and specific. Real-time PCR can provide results within hours and can distinguish toxigenic from non-toxigenic strains. PCR is particularly useful for confirming CDI in cases where toxin immunoassays are negative but clinical suspicion remains high [15, 14].

Culture and Ribotyping

Anaerobic culture of C. difficile from feces is performed using selective media containing cycloserine, cefoxitin, and fructose (CCFA) or chromogenic agar. After isolation, the organism can be characterized by ribotyping, which involves PCR amplification of the intergenic spacer region of the 16S-23S rRNA operon. Ribotyping is used for epidemiological surveillance and outbreak investigations [6, 3].

Differential Diagnosis

Other causes of acute diarrhea and colitis in horses must be excluded. These include Salmonella spp., Clostridium perfringens type A and C, Neorickettsia risticii (Potomac horse fever), cyathostomins (larval cyathostominosis), and non-infectious causes such as NSAID toxicity and dietary indiscretion. Co-infection with C. perfringens type C and C. difficile has been documented in foals, highlighting the need for comprehensive diagnostic testing [12].

Treatment

Treatment of C. difficile colitis in horses involves supportive care, antimicrobial therapy directed against the vegetative form of the organism, and measures to control toxemia.

Supportive Care

Fluid and electrolyte therapy is critical to correct dehydration and metabolic acidosis. Intravenous crystalloid solutions, such as lactated Ringer's solution, are administered based on clinical assessment and serial monitoring of packed cell volume, total protein, and electrolyte concentrations. Colloidal support may be needed in hypoproteinemic patients.

Anti-inflammatory therapy with flunixin meglumine is commonly used to control endotoxemia and abdominal pain. However, NSAIDs should be used cautiously due to their potential to exacerbate gastrointestinal injury. Polymyxin B and hyperimmune plasma have been used as adjunctive therapies for endotoxemia.

Antimicrobial Therapy

Metronidazole is the first-line antimicrobial for equine CDI. It is administered orally or intravenously at a dose of 10 to 15 mg/kg every 6 to 8 hours. Metronidazole has good activity against C. difficile and is minimally disruptive to the colonic microbiota. Oral vancomycin is an alternative for refractory cases but is more expensive and carries concerns regarding selection for vancomycin-resistant enterococci.

The use of antimicrobials that precipitated the colitis should be discontinued whenever possible.

Fecal Microbiota Transplantation

Fecal microbiota transplantation (FMT) has been used in horses with recurrent or refractory CDI. The procedure involves administering a fecal suspension from a healthy donor horse via nasogastric tube or enema. FMT aims to restore the diversity and function of the colonic microbiota, thereby re-establishing colonization resistance. Evidence for its efficacy in horses is largely anecdotal, but it is considered a reasonable salvage therapy.

Control and Prevention

Control of C. difficile in equine populations relies on infection prevention measures, antimicrobial stewardship, and vaccination strategies.

Infection Control

C. difficile spores are resistant to many common disinfectants. Effective sporicidal agents include 10% bleach (sodium hypochlorite) and peracetic acid-based disinfectants. Environmental cleaning and disinfection of stalls, equipment, and contaminated surfaces are essential to reduce transmission. Isolation of affected horses and the use of dedicated equipment can limit nosocomial spread [4, 5].

Antimicrobial Stewardship

Judicious use of antimicrobials, particularly macrolides and other high-risk drugs, is the most important preventive measure. Avoiding unnecessary antimicrobial therapy and selecting agents with a lower risk of inducing CDI can reduce disease incidence. In foals being treated for R. equi pneumonia, measures to prevent exposure of the dam to antimicrobial residues are recommended [10].

Vaccination

Research into vaccines against C. difficile for horses has focused on toxin neutralization and anti-colonization immunity. Immunization of mares with binding domains of toxins A and B elicits serum and colostral antibodies that block toxin binding to intestinal epithelial cells [17]. These antibodies are passively transferred to foals via colostrum, providing protection during the neonatal period.

Vaccination of pony foals with the PS-II polysaccharide conjugate vaccine induces a serum IgM antibody response, suggesting that anti-polysaccharide immunity may reduce colonization [18]. The PSI polysaccharide has also been investigated as a vaccine component, with natural anti-PSI IgG antibodies detected in horse serum following natural exposure [2]. These findings support the feasibility of developing multivalent vaccines targeting both toxins and surface polysaccharides.

Public Health Considerations

Although this review focuses on equine disease, it is important to note that C. difficile is a zoonotic pathogen. Ribotypes found in horses, such as 014/020 and 078, are also associated with human CDI [6]. Veterinary personnel and horse owners should practice appropriate hygiene when handling diarrheic horses and contaminated materials.

Conclusion

Clostridium difficile is a major cause of antimicrobial-associated diarrhea and colitis in foals and adult horses. The pathogenesis involves toxin-mediated disruption of intestinal epithelial cell function and the host inflammatory response. Diagnosis requires a combination of GDH screening, toxin detection, and molecular confirmation. Treatment centers on supportive care and metronidazole therapy. Prevention relies on antimicrobial stewardship, environmental decontamination, and emerging vaccination strategies. Continued research into the molecular epidemiology, host-pathogen interactions, and vaccine development will further improve the management of this important equine enteric pathogen.

References

[1] Haywood LMB, Sheahan BJ. A Review of Epithelial Ion Transporters and Their Roles in Equine Infectious Colitis. Vet Sci. 2024. https://pubmed.ncbi.nlm.nih.gov/39453072/

[2] Jiao Y, Ma Z, Hodgins D, et al. Clostridium difficile PSI polysaccharide: synthesis of pentasaccharide repeating block, conjugation to exotoxin B subunit, and detection of natural anti-PSI IgG antibodies in horse serum. Carbohydr Res. 2013. https://pubmed.ncbi.nlm.nih.gov/23597587/

[3] Ossiprandi MC, Buttrini M, Bottarelli E, et al. Preliminary molecular analysis of Clostridium difficile isolates from healthy horses in northern Italy. Comp Immunol Microbiol Infect Dis. 2010. https://pubmed.ncbi.nlm.nih.gov/20004974/

[4] Båverud V, Gustafsson A, Franklin A, et al. Clostridium difficile: prevalence in horses and environment, and antimicrobial susceptibility. Equine Vet J. 2003. https://pubmed.ncbi.nlm.nih.gov/12875324/

[5] Båverud V. Clostridium difficile infections in animals with special reference to the horse. A review. Vet Q. 2002. https://pubmed.ncbi.nlm.nih.gov/12540137/

[6] Silva RO, Rupnik M, Diniz AN, et al. Clostridium difficile ribotypes in humans and animals in Brazil. Mem Inst Oswaldo Cruz. 2015. https://pubmed.ncbi.nlm.nih.gov/26676318/

[7] Weese JS, Staempfli HR, Prescott JF. A prospective study of the roles of clostridium difficile and enterotoxigenic Clostridium perfringens in equine diarrhoea. Equine Vet J. 2001. https://pubmed.ncbi.nlm.nih.gov/11469775/

[8] Barr BS, Waldridge BM, Morresey PR, et al. Antimicrobial-associated diarrhoea in three equine referral practices. Equine Vet J. 2013. https://pubmed.ncbi.nlm.nih.gov/22779907/

[9] Gustafsson A, Båverud V, Gunnarsson A, et al. The association of erythromycin ethylsuccinate with acute colitis in horses in Sweden. Equine Vet J. 1997. https://pubmed.ncbi.nlm.nih.gov/15338913/

[10] Båverud V, Franklin A, Gunnarsson A, et al. Clostridium difficile associated with acute colitis in mares when their foals are treated with erythromycin and rifampicin for Rhodococcus equi pneumonia. Equine Vet J. 1998. https://pubmed.ncbi.nlm.nih.gov/9844966/

[11] Arroyo LG, Weese JS, Staempfli HR. Experimental Clostridium difficile enterocolitis in foals. J Vet Intern Med. 2004. https://pubmed.ncbi.nlm.nih.gov/15515592/

[12] Uzal FA, Diab SS, Blanchard P, et al. Clostridium perfringens type C and Clostridium difficile co-infection in foals. Vet Microbiol. 2012. https://pubmed.ncbi.nlm.nih.gov/22177970/

[13] Gohari IM, Arroyo L, Macinnes JI, et al. Characterization of Clostridium perfringens in the feces of adult horses and foals with acute enterocolitis. Can J Vet Res. 2014. https://pubmed.ncbi.nlm.nih.gov/24396174/

[14] Silva RO, Ribeiro MG, Palhares MS, et al. Detection of A/B toxin and isolation of Clostridium difficile and Clostridium perfringens from foals. Equine Vet J. 2013. https://pubmed.ncbi.nlm.nih.gov/23452044/

[15] Carvalho GM, Ramos CP, Lobato FCF, et al. Laboratory diagnosis of Clostridioides (Clostridium) difficile infection in domestic animals: A short review. Anaerobe. 2022. https://pubmed.ncbi.nlm.nih.gov/35472506/

[16] Ramos CP, Lopes EO, Oliveira Júnior CA, et al. Immunochromatographic test and ELISA for the detection of glutamate dehydrogenase (GDH) and A/B toxins as an alternative for the diagnosis of Clostridioides (Clostridium) difficile-associated diarrhea in foals and neonatal piglets. Braz J Microbiol. 2020. https://pubmed.ncbi.nlm.nih.gov/32363568/

[17] Artiushin S, Timoney JF, Fettinger M, et al. Immunisation of mares with binding domains of toxins A and B of Clostridium difficile elicits serum and colostral antibodies that block toxin binding. Equine Vet J. 2013. https://pubmed.ncbi.nlm.nih.gov/23206274/

[18] Arroyo LG, Hodgins DC, Guest B, et al. Serum IgM antibody response to Clostridioides difficile polysaccharide PS-II vaccination in pony foals. Anaerobe. 2022. https://pubmed.ncbi.nlm.nih.gov/36064161/